on cerebrospinal fluid in MS were supported by an NIH clinical investigator career development award. In 1987, Dr. Rudick became Director of the Mellen Center. He has played key roles in several MS clinical trials, including pivotal registration trials of IFN?-1a (Avonex) and natalizumab (Tysabri) for relapsing remitting MS. He continues studies on immunologic changes in MS patients, has led development of new clinical and imaging measures for MS trials, and maintains a consultative clinical practice at the Mellen Center. Dr. Rudick has maintained continuous competitive grant funding from NIH and National Multiple Sclerosis Society for over 25 years. In addition to being Director of the Mellen Center, Dr. Rudick is Vice Chairman of Research and Development in the Neurological Institute and Co–Principal Investigator of a citywide Clinical and Translational Science Collaborative.

Kevin A. Schulman, M.D., M.B.A., is a professor of medicine and the Gregory Mario and Jeremy Mario Professor of Business Administration at Duke University. He is an associate director of the Duke Clinical Research Institute at the Duke University School of Medicine. At Duke’s Fuqua School of Business, he serves as director of the Health Sector Management Program, the Master of Management in Clinical Informatics, and the Center for the Study of Health Management. His other university affiliations include the Trent Center for Bioethics, Humanities and History of Medicine; the Duke Translational Research Institute Pilot Project Advisory Committee; and the Duke Global Health Institute. Dr. Schulman is a distinguished researcher who has received more than $34 million in research grants. His research interests include health services research and policy, including access to care and the impact of reimbursement and regulatory policies on clinical practice; health economics and economic evaluation in clinical research; and medical decision making, especially in patients with life-threatening conditions. He regularly teaches courses in biotechnology, health policy, and health IT strategy. Dr. Schulman has published more than 350 papers and book chapters; his peer-reviewed articles have appeared in the New England Journal of Medicine, the Journal of the American Medical Association, and Annals of Internal Medicine. He is a member of the editorial/advisory boards of the American Journal of Medicine, the American Heart Journal, Health Services Research, and Value in Health. A recipient of numerous awards, Dr. Schulman is a fellow of the American College of Physicians and an elected member of the American Society for Clinical Investigation. He has served as session chair and panelist at dozens of medical and health care conferences. Dr. Schulman has also served on numerous grant review committees for the NIH, the Robert Wood Johnson Foundation, and other bodies. He is a member of the advisory board for the Centre for Healthcare Policy and Management

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement